Boundless Bio
PublicBoundless Bio is now publicly traded
The data on this page reflects Boundless Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Mar 28, 2024
Last Round
Series C
May 16, 2023
Total Funding Raised
$377M
Company Overview
Boundless Bio operates in Biotech and is based in San Diego, California. Its recorded funding history includes a Series C round in May 2023.
Boundless Bio is a clinical-stage oncology company focused on developing innovative therapies that target extrachromosomal DNA to treat patients with oncogene amplified tumors.
Sector
Biotech
AI Layer
Non-AI
Boundless Bio Comparables
Compare Boundless Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Illudent Therapeutics | 68% | |
| EtiraRx | 62% |
For institutional investors. Book with your work email.
Boundless Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 28, 2024 | ||||
| Series C | May 16, 2023 | ||||
| Grant | Jun 16, 2022 | ||||
| Series B | Apr 28, 2021 | ||||
| Series A | Sep 19, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Boundless Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| National Cancer Institute | Grant |
| RA Capital Management | Series B, Series C |
| Cancer Grand Challenges | Grant |
| Vertex Ventures HC | Series B, Series C |
| Guggenheim Securities | IPO |
| Heartland Healthcare Capital | Series C |
For institutional investors. Book with your work email.
Boundless Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.